<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756078</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5816</org_study_id>
    <nct_id>NCT02756078</nct_id>
  </id_info>
  <brief_title>Clinical Performance Evaluation of Two Silicone Hydrogel Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-masked dispensing study where subjects will randomized into one
      of two lens sequences to wear each of two contact lens types for a 4-week period with each
      lens type.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2016</start_date>
  <completion_date type="Actual">October 2, 2017</completion_date>
  <primary_completion_date type="Actual">October 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall CLUE Comfort</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall CLUE Handling</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Overall Handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Haze</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Time to haze measure the maximum time a contact lens wearers can keep their eye open without their vision becoming hazy. It was a measure of how the drying of the contact lens surface with open eyes affects vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Wear Time</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Average lens wear time with the study lenses were recorded in hour at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Comfortable Wear Time</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Average comfortable lens wear time with the study lenses were recorded in hour at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Total Device Use Time and Comfortable Wear Time During Device Use</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Subjects reported the total duration of their digital device use and comfortable lens wear time during digital device use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort at the End of the Day</measure>
    <time_frame>Up to 4-Week Follow-up</time_frame>
    <description>Subjects graded the comfort level at the end of the day using 5- point scale (1=excellence, 2=very good, 3=good, 4=fair and 5=poor). The average end of day comfort grade was reported for each lens type.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Group 1 (TEST / CONTROL wear sequence)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (CONTROL / TEST wear sequence)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TEST Contact Lens</intervention_name>
    <arm_group_label>Group 1 (TEST / CONTROL wear sequence)</arm_group_label>
    <arm_group_label>Group 2 (CONTROL / TEST wear sequence)</arm_group_label>
    <other_name>senofilcon A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONTROL Contact Lens</intervention_name>
    <arm_group_label>Group 1 (TEST / CONTROL wear sequence)</arm_group_label>
    <arm_group_label>Group 2 (CONTROL / TEST wear sequence)</arm_group_label>
    <other_name>samfilcon A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
             receive a fully executed copy of the form.

          -  The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol.

          -  The subject must be between 18 and 40 years of age.

          -  The subject's vertex corrected spherical equivalent distance refraction must be in the
             range of -0.50 Diopters (D) to -8.00 D in each eye.

          -  The subject's refractive cylinder must be no more than -1.00 D cylindrical correction
             in each eye after vertexing to the corneal plane.

          -  The subject must have best corrected visual acuity of 0.20 or better in each eye.

          -  The subject must be a current wearer of daily, spherical, soft contact lenses (no
             bifocal or multifocal contact lenses, no extended wear or monovision) for at least 5
             days/week and at least 8 hours/day during the month prior to enrollment.

          -  The subject must be using digital devices (any combination of computers, tablets,
             smart phones etc.) for at least 8 hours over the course of a typical day.

          -  The subject should own a wearable pair of spectacles and wear them the day of the
             baseline visit.

          -  The subject must have normal eyes with no evidence of abnormality or disease that in
             the opinion of the investigator would contraindicate contact lens wear.

          -  The subject must meet normal eligibility conditions of binocular vision tests.

          -  The subject may not have any double vision at near with their habitual contact lens
             correction.

        Exclusion Criteria:

          -  Currently pregnant or lactating (subjects who become pregnant during the study will be
             discontinued).

          -  Any ocular or systemic allergies or diseases that may interfere with contact lens wear
             (at the investigator's discretion).

          -  Any systemic disease, autoimmune disease, or use of medication, which may interfere
             with contact lens wear (at the investigator's discretion).

          -  Use of any medication that causes side effects similar to side effects experienced
             when using digital devices, such as a subject reporting headaches associated with
             birth control pills (at the investigator's discretion).

          -  Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious
             immunosuppressive disease.

          -  Any active ocular infection.

          -  Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of
             recurrent corneal erosions, aphakia, or moderate or above corneal distortion.

          -  Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy,
             photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK),
             etc.).

          -  Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal
             staining, or any other abnormalities of the cornea which would contraindicate contact
             lens wear.

          -  Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which
             might interfere with contact lens wear.

          -  Any known hypersensitivity or allergic reaction to the study products.

          -  Participation in any contact lens or lens care product clinical trial within 7 days
             prior to study enrollment.

          -  History of binocular vision abnormality or strabismus.

          -  Employee of investigational clinic (e.g., Investigator, Coordinator, Technician).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Contact Lens Research, University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <results_first_submitted>September 28, 2018</results_first_submitted>
  <results_first_submitted_qc>September 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2018</results_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02756078/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02756078/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 200 subjects were enrolled into this study. Of the enrolled, 171 subjects were randomized and dispensed at least one study lens. Of the dispensed subjects, 127 completed the study while 44 subjects were discontinued.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon A/Samfilcon A</title>
          <description>All subjects that received the senofilcon A lens during the first period and the samfilcon A lens during the second period.</description>
        </group>
        <group group_id="P2">
          <title>Samfilcon A/Senofilcon A</title>
          <description>All subjects that received the samfilcon A lens during the first period and the senofilcon A lens during the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory Lens Fitting</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lens Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Lens Fitting</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled Subjects</title>
          <description>All subjects enrolled in the study, i.e. signed informed consent form.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall CLUE Comfort</title>
        <description>Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall CLUE Comfort</title>
          <description>Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="22.47"/>
                    <measurement group_id="O2" value="60.3" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -5 points was used. This margin is based on a 10% shift in the distribution of CLUE score.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>5.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.796</dispersion_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>8.73</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as Test (senofilcon A) minus Control (samfilcon A)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall CLUE Handling</title>
        <description>Overall Handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall CLUE Handling</title>
          <description>Overall Handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" spread="18.58"/>
                    <measurement group_id="O2" value="52.9" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -5 points was used. This margin is based on a 10% shift in the distribution of CLUE score.</non_inferiority_desc>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>13.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.701</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.34</ci_lower_limit>
            <ci_upper_limit>17.05</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as Test (senofilcon A) minus Control (samfilcon A)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Haze</title>
        <description>Time to haze measure the maximum time a contact lens wearers can keep their eye open without their vision becoming hazy. It was a measure of how the drying of the contact lens surface with open eyes affects vision.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Haze</title>
          <description>Time to haze measure the maximum time a contact lens wearers can keep their eye open without their vision becoming hazy. It was a measure of how the drying of the contact lens surface with open eyes affects vision.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="5.01"/>
                    <measurement group_id="O2" value="9.7" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -2 hour was used.</non_inferiority_desc>
            <param_type>Posterior mean difference</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.313</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <other_analysis_desc>Mean difference was calculated as senofilcon A minus samfilcon A.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Wear Time</title>
        <description>Average lens wear time with the study lenses were recorded in hour at each follow-up visit.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Wear Time</title>
          <description>Average lens wear time with the study lenses were recorded in hour at each follow-up visit.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="3.57"/>
                    <measurement group_id="O2" value="11.55" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -2 hour was used.</non_inferiority_desc>
            <param_type>Posterior mean difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as senofilcon A minus samfilcon A</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Comfortable Wear Time</title>
        <description>Average comfortable lens wear time with the study lenses were recorded in hour at each follow-up visit.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Comfortable Wear Time</title>
          <description>Average comfortable lens wear time with the study lenses were recorded in hour at each follow-up visit.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="3.73"/>
                    <measurement group_id="O2" value="9.6" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -2 hour was used.</non_inferiority_desc>
            <param_type>Posterior mean difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.261</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as senofilcon A minus samfilcon A</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Total Device Use Time and Comfortable Wear Time During Device Use</title>
        <description>Subjects reported the total duration of their digital device use and comfortable lens wear time during digital device use.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Total Device Use Time and Comfortable Wear Time During Device Use</title>
          <description>Subjects reported the total duration of their digital device use and comfortable lens wear time during digital device use.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.74"/>
                    <measurement group_id="O2" value="1.2" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -2 hour was used.</non_inferiority_desc>
            <param_type>Posterior mean difference</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.159</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as senofilcon A minus samfilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comfort at the End of the Day</title>
        <description>Subjects graded the comfort level at the end of the day using 5- point scale (1=excellence, 2=very good, 3=good, 4=fair and 5=poor). The average end of day comfort grade was reported for each lens type.</description>
        <time_frame>Up to 4-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>All subjects that wore the samfilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort at the End of the Day</title>
          <description>Subjects graded the comfort level at the end of the day using 5- point scale (1=excellence, 2=very good, 3=good, 4=fair and 5=poor). The average end of day comfort grade was reported for each lens type.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.21"/>
                    <measurement group_id="O2" value="2.7" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 0.67 was used.</non_inferiority_desc>
            <param_type>Posterior odds ratio</param_type>
            <param_value>1.35</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.203</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>Odds ratio was calculated as senofilcon A over samfilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 8 weeks per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon A</title>
          <description>All subjects that wore the senofilcon A lens during either the first or second period of the study.</description>
        </group>
        <group group_id="E2">
          <title>Samfilcon A</title>
          <description>All subjects that wore the samfilcon A lens during either period of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Non-significant Infiltrative Event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Allergic Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant - Swollen Caruncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Conjunctival Redness and Staining</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Bulbar Redness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Grade 3-4 Conjunctival Staining</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Symptoms, Problems or complaints requiring treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Bacterial Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Keratoconjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Limbal Nodules</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Foreign Body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Stye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Bulbar and Limbal Redness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Localized Allergic Reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Corneal Tissue Overgrowth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant slit lamp finding Grade 2 or less requiring treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Conjunctival Redness Grade 3 or Higher</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Reaction to Eye Drop</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Phlyctenules</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Superficial Deposits</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Blurred Central Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Superior Arcuate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Localized Corneal Staining</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Ocular Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Redness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Patient Reported.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Difficulty opening eye</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-significant Stye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Stomach Flu</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chantal Coles-Brennan - PRINCIPAL RESEARCH OPTOMETRIST</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care, Inc.</organization>
      <phone>1-904-443-3449</phone>
      <email>CColesb@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

